A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus

Cellular and Molecular Immunology

Volumn 6, Issue 6, 2009, Pages 461-467

  Jin, Ouyang ^a   Zhang, Huayong ^a   Gu, Zhifeng ^a   Zhao, Shengnan ^a   Xu, Ting ^a   Zhou, Kangxing ^a   Jiang, Bo ^a   Wang, Jie ^a   Zeng, Xiaofeng ^b   Sun, Lingyun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Artesunate; Lupus nephritis; MRL lpr mice; Systemic lupus erythematosus

Indexed keywords

ARTESUNATE; B CELL ACTIVATING FACTOR; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTINUCLEAR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MORTALITY; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL TISSUE; ANTIBODY TITER; DISEASE COURSE; DRUG EFFECT; LUPUS ERYTHEMATOSUS NEPHRITIS; PROTEIN URINE LEVEL; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ARTEMISININS; B-CELL ACTIVATING FACTOR; BODY WEIGHT; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PILOT PROJECTS; PROTEINURIA;

ARTESUNATE; MURINAE; MUS;

EID: 73649099859     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.58     Document Type: Article

References (22)

1. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford). 2000;39:399-406.
2. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus-what's hot and what's not!. Rheumatology (Oxford). 2009;48:332-341.
3. Li XY. Immunomodulating Chinese herbal medicines. Mem Inst Oswaldo Cruz. 1991;86:159-164.
4. Ramgolam V, Ang SG, Lai YH, Loh CS, Yap HK. Traditional Chinese medicines as immunosuppressive agents. Ann Acad Med Singapore. 2000;29:11-16.
5. Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust. 2005;182:181-185.
6. Davis TM, Phuong HL, Ilett KF, et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2001;45: 181-186.
7. Noori S, Naderi GA, Hassan ZM, Habibi Z, Bathaie SZ, Hashemi SM. Immunosuppessive activity of a molecule isolated from Artemisia annua on DTH responses compared with cycrlosporin A. Int Immunopharmacol. 2004;4:1301-1306.
8. Dong YJ, Li WD, Tu YY. Effect of dihydro-qinghaosu on auto-antibody production, TNF alpha secretion and pathologic change of lupus nephritis in BXSB mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;23:676-679.
9. Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-κ and blocking the signaling pathway NF-κB translocation. Int Immunopharmacol. 2006;6:1243-1250.
10. Lan Lu. Study on effect of cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;22:169-171.
11. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8: 487-496.
12. Ju ZL, Shi GY, Zuo JX, Zhang JW, Jian Sun. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology. 2007;120:281-289.
13. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-1710.
14. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-999.
15. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111-2114.
16. Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-κB translocation. Int Immunopharmacol. 2006;6:1243-1250.
17. Ouyang Jin, Huayong, Xuting Zhang, et al. Pathological Change and Mechanism of Artesunate Treatment for Lupus Nephritis in MRL/lpr Mice. Shi Yong Lin Chuang Yi Yue Za Zhi. 2007;11: 5-9.
18. Tesch GH, Maifert S, Schwarting A, et al. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med. 1999;190:1813-1824.
19. Shimizu S, Nakashima H, Masutani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford, England). 2004;43: 1121-1128.
20. Mackay F, woodcock P, Lawton C, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-1710.
21. Ju ZL, Shi GY, Zuo JX, et al. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology. 2007;120:281-289.
22. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111-2114.